Positive feedback from European Medicines Agency on XF-73 Nasal gel Phase 3 programme
Phase 3 can use similar primary endpoint to the very successful Phase 2b clinical study
New European report underpins clinical need and market opportunity of XF-73 Nasal
Brighton, United Kingdom, 8 February 2022 – Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, has received positive Scientific Advice from the European Medicines Agency (EMA) following its review of Destiny Pharma’s proposed Phase 3 clinical programme design. This pivotal Phase 3 programme is expected to lead to the registration of the XF-73 nasal gel as a new drug in Europe.
The Company also announces findings from a recently commissioned, independent market research study which reinforces the clinical support and market potential of XF-73 Nasal gel in Europe.